Page last updated: 2024-10-24
cefuroxime and Inflammatory Response Syndrome, Systemic
cefuroxime has been researched along with Inflammatory Response Syndrome, Systemic in 1 studies
Cefuroxime: Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.
cefuroxime : A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Seyrek, M | 1 |
| Binbay, M | 1 |
| Yuruk, E | 1 |
| Akman, T | 1 |
| Aslan, R | 1 |
| Yazici, O | 1 |
| Berberoglu, Y | 1 |
| Muslumanoglu, AY | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Neutrophil and Lymphocyte Counts and the Neutrophil-to-lymphocyte Ratio as a Predictor of Fever Following Percutaneous Nephrolithotomy in Patients Without Risk Factors[NCT03774940] | | 519 participants (Actual) | Interventional | 2005-01-01 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trials
1 trial available for cefuroxime and Inflammatory Response Syndrome, Systemic